Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959326 | 1.00 | PIK3CA (0.41) | PIK3CAPIK3R1GAAALDH1A1L3MBTL1 | |
| SCHEMBL21253526 | 0.78 | PIK3CA (0.63) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL17822188 | 0.76 | PIK3CA (0.39) | PIK3CAPIK3R1ALDH1A1L3MBTL1MTOR | |
| SCHEMBL189813 | 0.76 | PIK3CA (0.49) | PIK3CAPIK3R1MTORPOLBPIK3CD | |
| SCHEMBL12166240 | 0.75 | PIK3CA (0.51) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL13298749 | 0.75 | PIK3CA (0.48) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL13059936 | 0.75 | PIK3CA (0.50) | PIK3CAPIK3R1ALDH1A1MTORMAPK1 | |
| SCHEMBL17822189 | 0.73 | PIK3CA (0.56) | PIK3CAPIK3R1MTORPOLBMAPK1 | |
| SCHEMBL17834982 | 0.71 | PIK3CA (0.68) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL29959501 | 0.71 | PIK3CA (0.68) | PIK3CAPIK3R1MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | claimed |
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | disclosed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-107074873-B | 7- (morpholinyl) -2- (N-piperazinyl) methylthioeno [2, 3-c ] pyridine derivatives as anticancer agents | 纳科法尔马有限公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NR2C2, NRDC, NDC1 | PIK3CA 1439/4885PIK3R1 2256/4885GAA 4665/4885 |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | PRMT7, CDK7, CASP7 | PIK3CA 1853/4885PIK3R1 2537/4885GAA 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.